Natixis’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Natixis’s Portfolio ARIA Stock Details ARIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-120,000	Closed	-$1.64M	–	928
2016 Q3	$1.64M	Buy	+120,000	New	+$1.2M	0.02%	283
2016 Q1	–	Sell	-18,800	Closed	-$118K	–	392
2015 Q4	$118K	Hold	18,800	–	–	﹤0.01%	287
2015 Q3	$110K	Hold	18,800	–	–	﹤0.01%	289
2015 Q2	$155K	Sell	18,800 -46,000	-71%	-$407K	﹤0.01%	342
2015 Q1	$534K	Buy	64,800 +34,800	+116%	+$257K	0.01%	294
2014 Q4	$206K	Hold	30,000	–	–	﹤0.01%	354
2014 Q3	$162K	Hold	30,000	–	–	﹤0.01%	393
2014 Q2	$191K	Sell	30,000 -43,450	-59%	-$299K	﹤0.01%	438
2014 Q1	$592K	Buy	+73,450	New	+$572K	0.01%	352

Other funds holding ARIA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Natixis's ARIA Position: Q4 2016 in Review

Natixis sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 120,000 shares — an estimated $1.64M sold.

Natixis first reported a position in ARIA in Q1 2014 and held it in 9 quarters. The position peaked at $1.64M in Q3 2016. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

Natixis reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
Natixis sold 120,000 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $1.64M.
Natixis first reported a position in Ariad Pharmaceuticals Inc in Q1 2014 and held it in 9 quarters.
Natixis's Ariad Pharmaceuticals Inc position peaked at $1.64M in Q3 2016.
200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on Natixis's 13F filing for Q4 2016, filed 14 Feb 2017.